The global Preclinical Oncology market size was accounted at USD 1,020.2 Mn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 10.6% from 2022 to 2030. The rise of immuno-oncology therapy such as T cell therapy, bispecific antibodies, immune checkpoint modulators, and personalized cancer vaccines compels the need for unique preclinical and translational service solution. Recently advances in Immuno-oncology industry with success of CAR-T Therapy boosted the R&D activities in the oncology industry which boost the demand for preclinical oncology models such as humanized models and syngeneic tumor models. The need for predictive approaches and robust preclinical models to minimize translational failures in immuno-oncology is very high. The factors such as early identification of predictive biomarkers, leveraging phenotypic features of models,and the need of rational design of combination therapies drive the growth of the oncology preclinical models market. The global preclinical oncology models market size was valued at US$ 1,020.2 Million in 2021, and it is expected to reach US$ 2,463.7 Million in 2030, recording a promising CAGR of 10.6% from 2022 to 2030.
The global oncology preclinical models market is segmented on the basis of product, application, and region. Based on the products, the market is divided into Syngeneic Models, Cell Lines Models, Orthotopic Tumor Models, and Others based on application type, the market is segmented into Neuroblastoma, Prostate Cancer, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer, Fibrosarcoma, Kidney Cancer, Liver Cancer, Lung Cancer, Lymphoma, Skin Cancer and Others.
Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that North America held the largest share of the market, followed by Europe and the Asia Pacific. The Asia Pacific is expected to grow at a rapid pace during the analysis of the forecast period. The key players of this market include Aragen Bioscience, vivoPharm Pty. Ltd. Bioduro, Crown Bioscience Inc., Charles River, Champion Oncology, Inc., Envigo, GenOway S.A., Hera BioLabs, MI Bioresearch Inc, Pharmatest Services, Taconic Biosciences, Inc., and The Jackson Laboratory.
